Skip to Content

Jefferies Financial Group predicts Integra LifeSciences Holdings Co. will earn $3.34 per share in fiscal year 2022. (NASDAQ:IART)

Jefferies Financial Group predicts Integra LifeSciences Holdings Co. will earn $3.34 per share in fiscal year 2022. (NASDAQ:IART)

Integra LifeSciences Holdings Corporation is traded on the NASDAQ under the symbol IART. In a research note distributed to investors on Tuesday, January 10, Jefferies Financial Group announced an increase in the estimates they had previously provided for Integra Lifescience’s earnings per share for the fiscal year 2022. The previous projection that M. Taylor, an analyst working for Jefferies Financial Group, had made for the profits per share of the life sciences business was raised to $3.34 from $3.30. Jefferies Financial Group’s investment firm has provided the company with a “hold” recommendation and forecasted that the share price would rise to $48.00 in the near future. According to the consensus estimate, earnings for the full year are expected to be $3.30 per share for Integra LifeSciences. Furthermore, according to Jefferies Financial Group projections, Integra LifeSciences will earn $0.93 per share in the fourth quarter of 2022, $3.65 per share in the fiscal year 2023, and $3.98 per share in the fiscal year 2024.

On October 26, the most recent quarterly earnings report for Integra LifeSciences (NASDAQ: IART) was made available to the public. Earnings per share for the period covered by the report from the life sciences business came in at $0.86, which was $0.14 higher than the estimate reached by the market analysts as a whole. In addition, Integra Lifesciences had a return on equity of 16.41% and a net margin of 11.05%. Both of these figures are percentages. The revenue generated during the quarter was anticipated to be anywhere from $377.79 million to $385.19 million, according to the estimates provided by analysts.

Thursday marked the first day of trading for IART shares, and the opening price was $58.14 per share. The ratio of the current ratio to the quick ratio is 2.91, while the ratio of the current ratio to the quick ratio is 3.93. The ratio of debt to equity is 0.86. Its price-to-earnings ratio (PE ratio) is 28.22, its price-to-earnings-to-growth ratio (P/E/G ratio) is 1.65, and its beta value is 1.14. The market capitalization of the company is $4.86 billion. The company’s moving average over the past 50 days is $54.81, and its moving average over the past 200 days is $51.59, respectively. Over the last 52 weeks, Integra LifeSciences has fluctuated between $40.67 and $69.90, with a price of $69.90 serving as the average.

CART has been the subject of research that has been carried out and reported on in a variety of study reports. Previously, the shares of Integra Lifesciences were assigned a rating of “c+.” However, in a report made public on Tuesday, December 27, TheStreet assigned the shares a rating of “b-,” an upgrade from the previous rating. Citigroup upgraded the stock from a “neutral” rating to a “buy” rating in a research report released on Monday, December 12. Additionally, the firm increased its price objective for Integra LifeSciences from $50.00 to $60.00. In addition, $10 was added to the total budget for the price goal. In a report made public on Thursday, October 27, JMP Securities lowered the “market outperform” rating that they had previously assigned to Integra LifeSciences and lowered their price target for those shares from $85.00 to $75.00. began providing coverage of Integra Lifesciences shares in a report published on October 12. The consensus recommendation for the stock was a “buy.” In a research report published on Friday, January 6, Morgan Stanley raised their price objective on Integra Lifesciences shares from $50.00 to $59.00 and rated the company as “equal weight.” This was the last and most recent piece of news regarding the company. The stock has been recommended to sell by one of the equity research analysts, a recommendation to hold it by four, and a rating to buy by two analysts. According to information provided by Bloomberg, the price target for the company has been established at $59.29, and the current consensus rating for the company is “Hold.”

As a result of the recent activity in the market, several hedge funds have recently made adjustments to their holdings of the stock. During the third quarter of the fiscal year, Wipfli Financial Advisors, LLC, invested in the form of a capital contribution to Integra LifeSciences for $29,000. During the third quarter, Neo Ivy Capital Management invested 30,000 dollars in Integra LifeSciences, establishing a new stake in the company. First Horizon Advisors, Inc. made a new investment of $54,000 in Integra Lifesciences during the second quarter, establishing a new stake in the company. The ownership stake in Integra Lifesciences that Quadrant Capital Group LLC holds reached a new all-time high of 595.7% during the company’s third-quarter reporting period. Quadrant Capital Group LLC now owns a total of 1,294 stock held by the life sciences company, following the acquisition of an additional 1,108 shares during the most recent quarter. There is a value of $55,000 associated with these shares. Aubrey Capital Management Ltd. made a brand-new investment in the amount of $76,000 in Integra Lifesciences during the second quarter, bringing us to our last and final point. Institutional investors and hedge funds jointly own 87.60% of the company’s total shares, which means that these two types of investors hold the majority of the company’s stock.

Integra LifeSciences Holdings Corporation designs, produce and sells surgical implants and equipment. Their products have applications in a variety of s


Leave a comment

Your email address will not be published. Required fields are marked *